The DSRU has recruited new research fellow, Samantha Lane, to start a new project to measure the impact of product withdrawals and other major pharmacovigilance actions on the public health burden since the implementation of the EU PV legislation in 2012. The results will be compared with those of two previous DSRU studies which looked at evidence used to support product withdrawals covering the periods 1999-2001 and 2002-2011.
One of the key priorities of PRAC’s Strategy on Measuring the Impact of Pharmacovigilance Activities (adopted January 2016) was the creation of an ENCePP Special Interest Group (SIG) on Impact, of which DSRU Director, Prof Saad Shakir, is a member. Sam’s project will form the DSRU’s contribution to the ENCePP SIG.
Sam is pictured here (R) with Saad Shakir and Liz Lynn.
- Obituary: Dr Richard Tiner MBBS DRCOG PFPM
- What will the role of UK Pharmacovigilance be after the UK leaves the EU?
- DSRU are pleased to announce a new two day course on Medication Errors
- Quantitative measurement of the impact of Pharmacovigilance decisions
- Designing studies for risk management plans that are acceptable to European regulators